Omalizumab treatment for chronic spontaneous urticaria: data from Turkey.
| Autor: | Kara RO; Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey., Dikicier BS; Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey., Yaldiz M; Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey., Koku B; Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey., Çosansu NC; Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey., Solak B; Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Postepy dermatologii i alergologii [Postepy Dermatol Alergol] 2022 Aug; Vol. 39 (4), pp. 704-707. Date of Electronic Publication: 2022 Sep 01. |
| DOI: | 10.5114/ada.2021.109081 |
| Abstrakt: | Aim: The aim of the study was to investigate data from patients suffering from chronic spontaneous urticaria refractory to conventional therapy, and to document outcomes of omalizumab use. Material and Methods: We conducted a single-centre retrospective study with 175 chronic spontaneous urticaria patients who were treated with 300 mg omalizumab subcutaneously every 4 weeks for at least 6 months. Efficacy, factors affecting outcome, and complications were examined. Results: The complete response rate was 70.9%. Minor complications were observed in 12% of our patients. Anaphylaxis occurred in 1 patient as a major complication. We did not notice any clinical or laboratory factors predicting response to omalizumab treatment. Conclusions: The findings show that omalizumab is effective and safe for the treatment of chronic spontaneous urticaria with a dosing of 300 mg/month subcutaneously. However, due to 1 case of anaphylaxis in this small group, we must still remind practitioners to be alert for this possible complication. (Copyright: © 2022 Termedia Sp. z o. o.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|